Literature DB >> 10412176

[Peritoneal mesothelioma--incidence and etiology].

V Neumann1, K M Müller, M Fischer.   

Abstract

A total of 70 malignant and 4 benign peritoneal mesotheliomas were diagnosed by the German Mesothelioma Registry between 1992 and 1998. Malignant mesotheliomas developed mainly in men (55/70); only one man had a benign peritoneal alteration. Age at first diagnosis of malignant mesotheliomas is about 59 years; the women are on average 4 years younger than the men. Mean survival time ranges about 1 year; in 6 of 38 patients longer survival times of up to 7 years are known. The epitheloid subtype predominates, but no effect on survival time is noticed. The percentage of patients with combined asbestos-associated lung fibrosis is higher than that for pleural mesotheliomas; these patients become ill about 6.5 years earlier. The latency period is 36 years on average. For most patients asbestos exposure is related to their occupation mainly in metal industries, asbestos industries, and in the building trade. There is no evidence for an induction of benign peritoneal alterations by asbestos dust.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412176     DOI: 10.1007/s002920050340

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  10 in total

1.  Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases.

Authors:  Yue Zhu; Nader Hanna; Cherif Boutros; H Richard Alexander
Journal:  J Gastrointest Oncol       Date:  2013-03

2.  Experience with peritoneal mesothelioma at the Milan National Cancer Institute.

Authors:  Marcello Deraco; Dario Baratti; Antonello Domenico Cabras; Nadia Zaffaroni; Federica Perrone; Raffaella Villa; Jenny Jocollè; Maria Rosaria Balestra; Shigeki Kusamura; Barbara Laterza; Silvana Pilotti
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

3.  Malignant peritoneal mesothelioma.

Authors:  Stine Munkholm-Larsen; Christopher Q Cao; Tristan D Yan
Journal:  World J Gastrointest Surg       Date:  2009-11-30

Review 4.  Peritoneal mesothelioma: a review.

Authors:  Alessio Bridda; Ilaria Padoan; Roberto Mencarelli; Mauro Frego
Journal:  MedGenMed       Date:  2007-05-10

Review 5.  [Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas].

Authors:  Volker Neumann; Stefan Löseke; Andrea Tannapfel
Journal:  Med Klin (Munich)       Date:  2009-10-25

6.  Factors influencing long-term survival in mesothelioma patients--results of the German mesothelioma register.

Authors:  V Neumann; A Rütten; M Scharmach; K-M Müller; M Fischer
Journal:  Int Arch Occup Environ Health       Date:  2004-02-27       Impact factor: 3.015

Review 7.  Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy.

Authors:  Martin D Goodman; Sarah McPartland; Danielle Detelich; Muhammad Wasif Saif
Journal:  J Gastrointest Oncol       Date:  2016-02

8.  Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma.

Authors:  Krishna Pillai; Mohammad Hossein Pourgholami; Terence C Chua; David Lawson Morris
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-06       Impact factor: 4.553

Review 9.  Peritoneal mesothelioma.

Authors:  Faheez Mohamed; Paul H Sugarbaker
Journal:  Curr Treat Options Oncol       Date:  2002-10

Review 10.  Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Gabriel Glockzin; Hans J Schlitt; Pompiliu Piso
Journal:  World J Surg Oncol       Date:  2009-01-08       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.